GYRE (Gyre Therapeutics) Accounts Payable : $0.1 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Accounts Payable?

Gyre Therapeutics's Accounts Payable for the quarter that ended in Dec. 2024 was $0.1 Mil.

Gyre Therapeutics's quarterly Accounts Payable increased from Jun. 2024 ($0.3 Mil) to Sep. 2024 ($0.3 Mil) but then declined from Sep. 2024 ($0.3 Mil) to Dec. 2024 ($0.1 Mil).

Gyre Therapeutics's annual Accounts Payable increased from Dec. 2022 ($0.1 Mil) to Dec. 2023 ($0.4 Mil) but then declined from Dec. 2023 ($0.4 Mil) to Dec. 2024 ($0.1 Mil).

Gyre Therapeutics Accounts Payable Historical Data

The historical data trend for Gyre Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Accounts Payable Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Accounts Payable

0.25

0.12

0.36

0.11

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Accounts Payable	Get a 7-Day Free Trial						0.36	0.33	0.27	0.30	0.11

Gyre Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Gyre Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.